image2.png
Starget Pharma and Cancer Focus Fund Announce $5.1 Million Investment to Support Phase 1b Clinical Trial of Novel Peptide Radioligand for Precision Cancer Therapy
October 23, 2024 07:00 ET | Cancer Focus Fund; Starget Pharma
Cancer Focus Fund invested $5.1M in precision peptide radioligand developer Starget for a Phase 1b trial at MD Anderson of its lead theranostic DOTA-PTR-58
image2.png
Eisbach and Cancer Focus Fund Announce $4.5 Million Investment to Support First-in-Human Phase 1/2 Trial of EIS-12656 for Refractory Advanced Solid Tumors
March 21, 2024 07:00 ET | Cancer Focus Fund; Eisbach Bio GmbH
Cancer Focus Fund is investing $4.5M for clinical trial of Eisbach's novel approach using synthetic lethality to kill PARP inhibitor resistant tumors